Notably, IFN‐λ emerges as a promising therapeutic target for counteracting the NR4A2 upregulation induced by BaP, thereby exhibiting promising anti‐COVID‐19 activity in the BaP‐exposed populations. The gene discussed is NR4A2; the disease is COVID-19.